Skip to main content
REVB logo

REVB · Revelation Biosciences, Inc.

Track REVB — free
$3.71 +0.02 (+0.54%)
Market Cap
$2.52M
Shares
683,442
Volume · Nov 20 1857 Avg daily vol (23 sessions) 20.32K

Price & Indicators

 

Key stats

Close
$3.69
Thu 19 Nov
Open
$3.69
Thu 19 Nov
Average volume, 30 days
21K
shares a session
Short interest
13K
1.9% of shares · 1.0 days to cover
Day range
$3.60$3.96
Open $3.69 Close $3.69
52-week closing range
$3.20$26.57
Close $3.69 86.1% under the high
Short volume, last session
31%
Latest filing
10-Q · Nov 5
Price history
Nov 2020 to Nov 2026

Latest documents

2026
Nov 13
Current report 8-K
Social media designated for potential material disclosures

Revelation Biosciences, Inc. said it may use social media channels to communicate material information and comply with Regulation FD, while clarifying that such disclosures are neither furnished nor filed under the Securities Exchange Act of 1934.

Regulation FD disclosure
2 source passages
Revelation Biosciences, Inc. (the “Company”) wishes to notify the investment community and others that in the future, we may choose to communicate material information about us and our services and for complying with our disclosure obligation under Regulation FD via social media channels. Neither the information in this Item 7.01 or any social media post are to be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act. Open the document at this passage
Nov 5
Current report 8-K
Funding through second quarter of 2027 depends on operating plans

Revelation Biosciences, Inc. reported $9.1 million in cash as of September 30, 2026 and, based on current operating plans and projections, believes it can fund operations into the second quarter of 2027; nine-month net loss was $9.6 million.

Financial results
3 source passages
As of September 30, 2026, Revelation had $9.1 million in cash and cash equivalents, compared to $10.7 million as of December 31, 2025. Based on current operating plans and projections, Revelation believes its current cash and cash equivalents are sufficient to fund operations into the second quarter of 2027. Net loss for the nine months ended September 30, 2026 was $9.6 million, or $29.37 basic and diluted net loss per share compared to net loss of $6.4 million, or $273.33 basic and diluted net loss per share for the nine months ended September 30, 2025. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash shortage and Nasdaq delisting risk

Revelation says cash is insufficient, raising substantial going-concern doubt, with $9.1 million available and a $59.1 million deficit as of September 30, 2026; Nasdaq delisting is possible if market value stays below $5 million for 30 consecutive business days.

Net loss $3.32M Diluted EPS -$5.92
Read from the MD&A section
5 source passages
We do not anticipate that our current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that our unaudited financial statements for September 30, 2026 were issued, which raises substantial doubt about our ability to continue as a going concern. As of September 30, 2026 we had an accumulated deficit of $59.1 million, a stockholders’ equity of $7.2 million and available cash and cash equivalents of $9.1 million. Revelation’s common stock and Public Warrants are listed on the Nasdaq Capital Market listing tier (“Nasdaq Capital Market”) under the symbols “REVB” and “REVBW,” respectively. The new MVLS Rule eliminates any cure period, precludes any automatic stay of suspension pending an appeal, and results in an immediate trading suspension upon Nasdaq’s determination of non-compliance. Given that the current market value of the Company’s listed securities is below $5 million, the MVLS Rule would result in the delisting of the Company’s securities from Nasdaq should the market value of its listed securities remain below $5 million for 30 consecutive business days. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$12.16M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 6,085.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$9.12M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+492.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.9%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −49%
below
Price vs 50-day avg −25%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 2%
near low
Momentum
relative strength
Weak
1-month return 0%
trailing
6-month return −52%
trailing
YTD return +15%
this year
Relative strength −46%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.87% of shares out · ▲ +1255.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
24 holders — mid 3-yr range
Squeeze score 59
elevated · 0–100
Fundamentals
Strong
EPS growth +98%
Y/Y
Free cash flow $-8.3M
Balance sheet $10.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 619%
annualized · 1-yr
Max drawdown −88%
past year
ATR 12.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−49% Bearish
Price vs 50-day avg
−25% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
2% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.87% of shares out · ▲ +1255.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
24 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $4 · 2% Range high $27
vs 200-day avg -49% vs 50-day avg -25%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
REVB
Revelation Biosciences, Inc.
this stock
$2.52M — — — 1.9%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
24
% held
205.1%
Net QoQ
-3.2K sh
Top holder
Linden Advisors LP
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Rising
Shares short
12.8K
Days to cover
1.0d
Change
+11.8K sh
View
Short Volume
Short vol %
31%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$4
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-8.9M
EPS diluted
$-167.65
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
22

Revelation Biosciences, Inc. said it may use social media channels to communicate material information and comply with Regulation FD, while clarifying that such disclosures are neither furnished nor filed under the Securities Exchange Act of 1934.

View
Proposed Sales
Value
$986
Shares
1.4K
Filed
Sep 28, 2023
View
Earnings & Events
Investor Relations
Latest news
Revelation Biosciences Announces…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
REVB -15.8% +0.3% -51.6% -8.4% +15.3%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -10.3% +6.6% -46.0% -3.2% +10.3%
Key facts CIK 1810560 CUSIP 76135L887 13F (30d) 16 filings 14 filers Visit website Investor relations